Proactive Investors - Run By Investors For Investors

Smith & Nephew shares weak on reports of talks over possible $3bn US orthopaedics acquisition

The Financial Times report, published online late on Friday, said the exact terms of the discussions had not been disclosed and added the talks may still not proceed to a deal
Knees
Nasdaq-listed, California-based NuVasive makes equipment for spinal surgery, as well as bone implants

Smith & Nephew PLC (LON:SN.) shares were weak on Monday after the Financial Times reported that the medical devices firm is in discussions to acquire US surgical instruments maker NuVasive Inc (NASDAQ:NUVA), a deal that could be worth more than US$3bn.

The FT report, published online late on Friday, said the exact terms of the discussions had not been disclosed and added the talks may still not proceed to a deal.

READ: Smith & Nephew up as annual profits surge after US$84mln legal win against insurers

Nasdaq-listed, California-based NuVasive makes equipment for spinal surgery, as well as bone implants.

Last Thursday, S&N posted strong annual results, with all three of its divisions showing increased revenue.

Last month, the UK group completed the US$105mln acquisition of another US orthopaedics firm, Ceterix Orthopaedics.

In early trading on Monday, S&N shares topped the FTSE 100 fallers list, down 2.7% at 1,473.50p.

NuVasive, which has a market cap of USD2.55bn, saw its shares spike 18% higher in US after-hours trading following the publication of the FT article,

View full SNN profile View Profile

Smith & Nephew PLC Timeline

Related Articles

porcupine
November 30 2018
It’s been a tricky period for Redx, but it has come through it with a promising pipeline, cash in the bank and AstraZeneca’s former UK boss as its new chief executive
Medical scanner
February 08 2019
The company’s digital platform and Artificial Intelligence (AI) software manages and helps interpret images from MRI (magnetic resonance imaging) and PRT (positron emission tomography) scanners
copd radiograph
April 02 2019
City broker Peel Hunt reckons the recent approvals “support the top-line forecasts in our model that should see Circassia achieve EBITDA positivity in 2020”
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use